Department of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Microbiol Spectr. 2023 Jun 15;11(3):e0349622. doi: 10.1128/spectrum.03496-22. Epub 2023 Apr 25.
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin. Genomics analysis and genetic complementation revealed that a frameshift mutation in contributed to cefiderocol resistance. Heterologous expression of or in Escherichia coli increased the host resistance to cefiderocol. Moreover, avibactam, a β-lactamase inhibitor, enhanced cefiderocol activity against the resistant strain. Therefore, cefiderocol resistance is linked to SHV and the loss of . Understanding cefiderocol resistance mechanisms is essential for providing solutions to treat infections and to prevent resistance development. Cefiderocol resistance in Klebsiella pneumoniae AR 0047 is linked to SHV β-lactamase activities and functional loss of outer membrane porin. The cefiderocol-avibactam combination represents an opportunity to increase potency against cefiderocol-resistant pathogens.
CDC 和 FDA 抗生素耐药分离库中的肺炎克雷伯菌 AR 0047 对头孢地尔可罗耐药,这是一种铁载体结合头孢菌素。基因组分析和遗传互补表明, 中的移码突变导致头孢地尔可罗耐药。 在大肠杆菌中的异源表达或 增加了宿主对头孢地尔可罗的耐药性。此外,β-内酰胺酶抑制剂阿维巴坦增强了耐药菌株对头孢地尔可罗的活性。因此,头孢地尔可罗耐药与 SHV 和 的缺失有关。了解头孢地尔可罗耐药机制对于提供治疗感染的解决方案和防止耐药性发展至关重要。肺炎克雷伯菌 AR 0047 的头孢地尔可罗耐药与 SHV β-内酰胺酶活性和外膜孔蛋白的功能丧失有关。头孢地尔可罗-阿维巴坦联合用药为增加对头孢地尔可罗耐药病原体的效力提供了机会。